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ABSTRACT
Hundreds of trials are being conducted to evaluate combination of newer targeted drugs as well as
immunotherapy. Our aim was to compare efficacy and safety of combination versus single non-cytotoxic
anticancer agents. We searched PubMed (01/01/2001 to 03/06/2018) (and, for immunotherapy, ASCO
and ESMO abstracts (2016 through March 2018)) for randomized clinical trials that compared a single
non-cytotoxic agent (targeted, hormonal, or immunotherapy) versus a combination with another non-
cytotoxic partner. Efficacy and safety endpoints were evaluated in a meta-analysis using a linear mixed-
effects model (guidelines per PRISMA Report).We included 95 randomized comparisons (single vs.
combination non-cytotoxic therapies) (59.4%, phase II; 41.6%, phase III trials) (29,175 patients (solid
tumors)). Combinations most frequently included a hormonal agent and a targeted small molecule
(23%). Compared to single non-cytotoxic agents, adding another non-cytotoxic drug increased response
rate (odds ratio [OR]=1.61, 95%CI 1.40-1.84)and prolonged progression-free survival (hazard ratio [HR]
=0.75, 95%CI 0.69-0.81)and overall survival (HR=0.87, 95%CI 0.81-0.94) (all p<0.001), which was most
pronounced for the association between immunotherapy combinations and longer survival.
Combinations also significantlyincreased the risk of high-grade toxicities (OR=2.42, 95%CI 1.98-2.97)
(most notably for immunotherapy and small molecule inhibitors) and mortality at least possibly therapy
related (OR: 1.33, 95%CI 1.15-1.53) (both p<0.001) (absolute mortality = 0.90% (single agent) versus
1.31% (combinations)) compared to single agents. In conclusion, combinations of non-cytotoxic drugs
versus monotherapy in randomized cancer clinical trials attenuated safety, but increased efficacy, with
the balance tilting in favor of combination therapy, based on the prolongation in survival.
ARTICLE HISTORY
Received 1 September 2019
Revised 17 November 2019
Accepted 29 November 2019
KEYWORDS
Combination therapy;
targeted therapy;
immunotherapy; hormonal
therapy; solid tumors
Introduction
Historically, cytotoxic agents have been the mainstay of treat-
ment for advanced cancers. Many combinations of cytotoxic
agents were tested in solid tumors, with additive/synergistic
mechanisms of action. In general, a paradigm has been estab-
lished for cytotoxic combinations, in which an increased
response rate is often observed along with increased
toxicities.1-4 Combining two different chemotherapeutic
agents with distinct mechanisms of action is also used in an
effort to minimize the evolution of the cancer and to attenuate
development of drug resistance.5 As a result, combinations of
cytotoxic agents became the standard of care for many
advanced solid tumors.
Treatment modalities in oncology are constantly evolving,
with a recent increase in approvals of classes of agents other
than chemotherapy. These newer agents include targeted
drugs, hormonal agents and immunotherapies.6 A better
understanding of cancer biology and pathogenesis lead to
molecular-targeted therapies. These agents are designed to
block specific-altered proteins that stimulate cell growth in
molecularly defined subsets of individuals. They may also
target proteins preferentially expressed on tumor versus nor-
mal cells. Targeted treatments may evoke major tumor
responses, usually with a better therapeutic index compared
to conventional cytotoxic agents, especially when using
a biomarker-driven strategy.7,8 Another cancer treatment
approach is based on immunotherapy, taking advantage of
the host immunological system to eradicate cancer cells.
Long-term control or even complete eradication of cancer in
a subset of patients is the great appeal associated with immu-
notherapy treatment.9 In addition, many solid tumors, includ-
ing breast and prostate cancer, are known to be sensitive to
hormonal manipulations.
In addition to increasing tumor response rates, combina-
tion therapy is a strategy to circumvent resistance to treat-
ment. Drug combinations can result in synergism, not only in
efficacy parameters but also in delaying disease progression by
impacting multiple intracellular escape pathways, crucial for
tumor cell growth and survival. The development of new
classes of anticancer agents ushered in a plethora of new
drug combinations trials in oncology. However, the kinetics
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of tumor responses and safety profile of non-cytotoxic agents
are distinct from those of chemotherapy. Previous studies
suggested a possible rationale for dosing combinations with
targeted and cytotoxic agents.10-12 Indeed, based on the cru-
cial role that combination treatments are likely to play in
improving outcome, more knowledge about the efficacy and
safety of combining non-cytotoxic agents for the treatment of
advanced solid tumors is needed.
We performed a systematic review of randomized trials
designed to treat advanced/metastatic cancer. Our objective
was to compare efficacy and safety of combination versus
single non-cytotoxic anticancer agents for the management
of advanced solid malignancies, establishing general para-
meters in common clinical trials endpoints for
combinations.
Results
Search results
Our search yielded 2,551 trials according to our search cri-
teria. We first excluded 2,400 after title review and another 63
were further excluded after abstract review (Figure S1). We
included 88 published randomized trials and 4 additional
trials presented as abstracts that evaluated immunotherapy
combinations. This led to a total of 95 randomized compar-
isons, as three trials included more than one randomized
comparison that fulfilled our criteria (Table S2). These trials
enrolled a total of 28,704 patients (13,381 in arms testing
single agents and 15,323 in arms testing combinations). Of
the 95 randomized comparisons, 57 (60%) were phase II trials
(Table 1). The three most frequent tumor types tested for
combinations were breast (29%), non-small cell lung cancer
(23%) and renal cancer (14%). The type of combination most
frequently evaluated included a hormonal agent as the back-
bone drug combined to a targeted small molecule in 23% of
randomized comparisons. The drug most frequently used as
the backbone for the combinations was erlotinib (20%), fol-
lowed by letrozole (9%) and bevacizumab (7%). Similarly,
erlotinib was also the most frequent experimental drug and
was present in 5% of combinations (Table S4).
Effects of combination on response rates
Of the 95 randomized comparisons, 88 reported results
enabling RR analysis. Overall, RR was higher on combina-
tions compared to single-agent drugs (OR = 1.61, 95%CI
1.40–1.84; p < .001) (Figure 1A). The overall response rate
was 17.4% versus 24.8% (p < .001) in single agents and
combination arms, respectively. The positive effect of com-
binations was observed regardless of other characteristics,
including tumor type, line of therapy or the biomarker-
based selection for the treatment. We observed that OR of
RR for combination therapy increased over time according
to the start of enrollment in each trials (p = .014).
The classes of the backbone drug had different effects
upon the efficacy of combinations. Although statistically
significant positive effects were observed for all classes,
immunotherapies, and drugs not classified were more posi-
tively influenced vis-a-vis response rate by the addition of
a second agent (Table 2) while targeted small molecules
were less impacted.
Effects of combinations on PFS
For this analysis, we included 71 randomized comparisons
(24 were excluded, 6 because PFS was not reported in any
form and 18 because only medians were published).
Overall, PFS was significantly better with combinations
compared to single-agent therapies (hazard ratio
[HR] = 0.75, 95%CI 0.69–0.81; p < .001) (Figure 1B). Of
the 18 trials that only reported median PFS, in 12 the
outcome was numerically longer in combination arms, in
3 it was similar and in another 3 it was shorter for combi-
nations. The class of the backbone agent and the tumor
Table 1. Characteristics of randomized clinical trials analyzed.a
Characteristics N (%)
Total randomized trials 92
Number of patients
-Single agent arm
-Combination arm
28,704
13,381 (46.6)
15,323 (53.4)
Total randomized comparisonsb
-Phase 2 trial
-Phase 3 trial
95 (100)
57 (60)
38 (40)
Types of Randomized Comparisons
-Targeted small molecule ± targeted small molecule
-Targeted small molecule ± targeted mABs
-Targeted small molecule ± immunotherapy
-Targeted small molecule ± hormonal
-Targeted small molecule ± other
-Targeted mABs ± targeted small molecule
-Targeted mABs ± targeted mABs
-Targeted mABs ± immunotherapy
-Immunotherapy ± immunotherapy
-Immunotherapy ± not classified
-Hormonal agent ± targeted small molecule
-Hormonal agent ± targeted mABs
-Hormonal agent ± hormonal agent
-Hormonal agent ± not classified
-Not classifiedc ± targeted small molecule
-Not classifiedc ± targeted mABs
-Not classifiedc ± hormonal agent
95
19 (20)
11 (11)
2 (2)
1 (1)
1 (1)
9 (9)
3 (3)
2 (2)
7 (7)
3 (3)
22 (23)
5 (5)
5 (5)
2 (2)
1 (1)
1 (1)
1 (1)
Biomarker-based rational for the combination
-Yes
-No
9 (9)
86 (91)
Tumor Types
-Breast
-Colorectal
-Endometrial
-GIST
-Head and Neck
-Hepatocellular carcinoma
-Malignant Mesothelioma
-Melanoma
-Neuroendocrine
-NSCLC
-Prostate
-Renal cell
-Sarcoma
-SCLC
95
28 (29)
6 (6)
1 (1)
2 (2)
3 (3)
3 (3)
1 (1)
3 (3)
1 (1)
22 (23)
9 (9)
13 (14)
1 (1)
1 (1)
aSee Methods for selection criteria.
bThree trials included to more than one randomized comparison.
cNot Classified included: prednisone, lenalidomide, cimetidine, retinoic acid,
simvastatin, zoledronic acid, alendronate, sargramostim. For a full list of
classification of agents see Table 1.
Abbreviations: GIST: gastrointestinal stromal tumor; mAB: monoclonal anti-
body; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer.
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type had significant interaction with the effect observed and
were included in the multivariate model. We observed
a trend for a better effect of combinations on PFS for
hormonal therapies as the backbone drug (HR 0.69,
p < .001) and a significant positive pronounced effect in
prostate (HR = 0.50, 95%CI 0.29–0.86; p = .01) and non-
small cell lung cancers (HR = 0.83, 95%CI 0.73–0.94;
p = .005) (Table 2).
Figure 1. Forest plot representing the odds ratio for response rate (A) and hazard ratios for PFS (B) and OS (C) for experimental arms with combination of therapies
compared to experimental arms with single-agent non-cytotoxic therapies. Studies are labeled by first author’s last name and year of publication and numbers in
brackets are labeled according to supplementary references. Panel A shows odds ratio (95% confidence interval) for response rate for each randomized trial
comparing combinations to single agents. The plot shows an overall increase in response rate for combinations: OR (95% CI) = 1.61 (1.40−1.84) (p < .001). Panel
B shows hazard ratio (95% confidence interval) for PFS for each randomized trial comparing combinations to single agents. The plot shows an overall increase in PFS
for combinations: HR (95% CI) = 0.75 (0.69–0.81) (p < .001). Panel C shows hazard ratio (95% confidence interval) for OS for each randomized trial comparing
combinations to single agents. The plot shows an overall increase in OS for combinations: HR (95% CI) = 0.87 (0.81–0.94) (p < .001).
Abbreviations: CI: confidence interval; NR: non-responders; OS: overall survival; PFS: progression-free survival; R: responders: RE model: random-effects model.
ONCOIMMUNOLOGY e1710052-3
Effects of combination on survival
For the survival analysis, we included 48 randomized com-
parisons (47 were excluded, 5 because OS estimates were
not reached, 25 because OS was not reported in any form
and 17 because only medians were published). Overall, OS
was significantly better with combinations compared to
single-agent therapies (HR = 0.87, 95%CI 0.81–0.94; p <
.001) (Figure 1C). Of the 17 trials that only reported
median OS, in 4 the outcome was numerically longer in
combination arms, in 9 it was similar and in another 4 it
was shorter for combinations. The class of the backbone
agent, tumor type and the median of prior regimens used
for the patients had significant interaction with the effect
observed and were included on the multivariate model. We
observed a significant positive pronounced effect of combi-
nations when immunotherapies and monoclonal antibodies
Figure 1. (continued).
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were selected as backbone drugs and a trend toward positive
effect when “not classified” drugs were selected. Tumor types less
sensitive to the positive effects of combinations included color-
ectal (trend), non-small cell lung cancer, and renal cell cancer,
while prostate cancer presented a more pronounced positive
effect of combinations. A positive effect was also observed for
trials whose patients had a median of only one or at least three
prior regimens (Table 2), with a trend toward positive effect with
two prior therapies.
Effect of combinations on high-grade toxicities and
treatment-related mortality
Seventy-six randomized comparisons were included for the
high-grade toxicity analysis. Overall, combinations increased
the risk of high-grade toxicities compared to single agents
(OR = 2.42, 95%CI 1.98–2.97; p < .001) (Figure 2A). Each
model had a decreasing linear dependence on the appropriate
toxicity rate in the single-agent arm. Specifically that higher
toxicity rates in the single-agent arm tended to have lower
Figure 1. (continued).
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odds ratios for the experimental arm (as one would expect).
After accounting for that covariate in an ANCOVA-like ana-
lysis in each case, the only characteristic that had an interac-
tion with the effect and was included on the adjusted model
was the class of the experimental agent (Table 3). The effects
on increased toxicity rate were most pronounced with tar-
geted small molecule and immunotherapy drugs added as an
additional agent, with a smaller, but still statistically signifi-
cant, increase for targeted monoclonal antibodies. The
increases in hormonal and “not classified” experimental
drugs were not statistically significant. Eighty-seven rando-
mized comparisons were used for the treatment-related mor-
tality analysis. Combinations significantly increased the risk of
treatment-related mortality (OR: 1.33, 95%CI 1.15–1.53; p <
.001) (Figure 2B). All classes of experimental drugs had sta-
tistically significant increases in treatment-related mortality in
the experimental arms, with the exception of when drugs “not
classified” were added as experimental agents, which had
a trend in the opposite direction (OR 0.53, 95%CI 0.26–1.07;
p = .08). The overall incidence of treatment-related deaths was
0.90% versus 1.31% (p < .001) in single agents and combina-
tions arms, respectively. As safety objectives are different
between phase II and phase III studies, we tested this variable
in our model, but for both analysis, there was no statistical
significance (high-grade toxicities, p-value 0.95; treatment-
related mortality, p-value 0.08, Table 3)
Discussion
The present meta-analyses of randomized trials of monother-
apy versus combination therapy in the non-cytotoxic setting
yielded several important findings. First, combinations of
non-cytotoxic drugs overall increased efficacy compared to
single-agent therapies, as demonstrated by higher RR (OR =
1.61, 95% CI 1.40–1.84; p < .001) and a PFS and OS benefit
(HR = 0.75, 95% CI 0.69–0.81 and HR = 0.87, 95%CI 0.81–-
0.94, respectively; both p < .001) (Figure 1). However, along
with this benefit, toxicity and treatment-related mortality
were also increased, although the absolute incidence of deaths
at least possibly related to drugs given in combinations is low
(~1.3%) and did not obviate the OS benefit of the combina-
tions. Indeed, one of the main findings from this study was
the fact that survival, the ultimate goal of cancer treatment,
was improved with the combination treatment strategy.13,14
Power to demonstrate a statistically significant gain in OS
can be limited among individual studies, with a need for large
Table 2. Meta-analysis for the effects of combination therapies versus single agents on outcome in randomized trials (multivariate)a.
Response rate PFS OS
N OR (95% CI) N HR (95% CI) N HR (95% CI)
Overall
P-value
88 1.61 (1.40–1.84)
<0.001
71 0.75 (0.69–0.81)
<0.001
48 0.87 (0.81–0.94)
<0.001
Class of backbone drug
Targeted small molecule inhibitors
Targeted monoclonal antibodies
Immunotherapy
Hormonal
Not classifiedb
33
12
9
31
3
1.31 (1.07–1.61)
p = .01
2.17 (1.55–3.02)
p < .001
2.13 (1.38–3.28)
p < .001
1.54 (1.27–1.87)
p < .001
4.71 (1.90–11.67)
p = .001
29
12
3
25
2
0.90 (0,59–1.36)p = .60
0.87 (0.53–1.44)
p = .59
0.64 (0.36–1.12)
p = .11
0.69 (0.61–0.78)
p < .001
1.32 (0.82–2.14)
p = .25
24
8
3
11
2
0.82 (0.57–1.17)
p = .26
0.57 (0.38–0.85)
p = .007
0.49 (0.33–0.74)
p = .001
0.95 (0.78–1.17)
p = .65
1.61 (0.97–2.65)
p = .06
Tumor Type
Breast Cancer
Colorectal Cancer
NSCLC
Prostate Cancer
RCC
Others
28
5
21
6
12
16
NS
NS
NS
NS
NS
NS
24
4
20
5
10
8
0.90 (0.59–1.36)
p = .60
0.83 (0.56–1.24)
p = .36
0.83 (0.73–0.94)
0.005
0.50 (0.29–0.86)
p = .01
0.82 (0.64–1.05)
p = .11
0.92 (0.72–1.18)
p = .50
9
4
18
6
7
4
0.82 (0.57–1.17)
p = .26
1.55 (0.94–2.56)
p = .08
1.32 (1.01–1.71)
p = .04
0.54 (0.38–0.77)
p = .001
1.27 (1.02–1.59)
0.035
0.98 (0.83–1.14)
p = .75
Median Number Prior Regimensc
0
1
2
3 or more
35
35
11
5
NS
NS
NS
NS
33
27
9
2
NS
NS
NS
NS
19
19
8
2
0.82 (0.57–1.17)
p = .26
0.59 (0.40–0.87)
p = .008
0.70 (0.45–1.07)
p = .09
0.76 (0.58–0.99)
p = .04
aSingle agents are the reference point for all statistics. The final model included the following variables in each category: RR (Backbone drug class and linear start of
enrollment year); OS (backbone drug class, tumor indication, and median prior regimens); PFS (backbone drug class and tumor indication).
bNot Classified included: prednisone, lenalidomide, cimetidine, retinoic acid, simvastatin, zoledronic acid, alendronate, sargramostim. For a full list of classification of
agents see Supplemental Table 1.
cTwo trials included in response rate analysis did not reported number of prior regimens.
Abbreviations: HR, hazard ratio; mAB: monoclonal antibody; N, number of randomized comparisons included; NS: not significant in (and therefore not included in)
multivariate model; NSCLC: non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; OR, odds ratio; RCC: renal cell carcinoma.
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sample size and long follow-up time. Disease-specific charac-
teristics can also interfere with information gained from
a single clinical trial that attempts to demonstrate a survival
benefit. As an example, in breast cancer, which was the most
frequent tumor type tested in combinations in our analysis,
median OS can be long, and patients frequently try multiple
therapies after progression on a clinical trial.15 As
a consequence, the chance of detecting a statistically signifi-
cant difference in OS after a clinical trial may be attenuated or
confounded by subsequent interventions. Specifically,
Figure 2. Forest plot representing the odds ratio for high-grade toxicities (A), and for treatment-related mortality (B) for experimental arms with combination of
therapies compared to experimental arms with single-agent non-cytotoxic therapies. Studies are labeled by first author’s last name and year of publication and
numbers in brackets are labeled according to supplementary references. Panel A shows odds ratio (95% confidence interval) for high-grade toxicities for each
randomized trial comparing combinations to single agents. The plot shows an overall increase in high-grade toxicities for combinations: OR (95% CI) = 2.42
(1.98−2.97) (p < .001). Panel B shows odds ratio (95% confidence interval) for treatment-related mortality for each randomized trial comparing combinations to
single agents. The plot shows an overall increase in treatment-related mortality for combinations: OR (95% CI) = 1.33 (1.15–1.53) (p < .001).
Abbreviations: CI: confidence interval; Non-Tox: number of patients without high-grade toxicities; OR: odds ratio; Tox: number of patients with high-grade toxicities:
RE model: random-effects model.
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combinations of cyclin-dependent kinase 4 and 6 (CDK4/6)
(palbociclib, ribociclib, and abemaciclib) with endocrine ther-
apy was well evaluated in our meta-analysis (a total of six
randomized comparisons) (for metastatic hormone receptor-
positive HER-2 negative breast cancer). Addition of these
drugs to endocrine therapy in the first-line setting led to an
absolute median PFS gain of about 10 to 15 months, but OS
benefit was not statistically significant or was not reached in
the individual trials.16-18 A previous analysis demonstrated
that the power of these pivotal first-line trials to demonstrate
a statistically significant improvement in OS is less than 70%
if the prolongation in median OS is less than 12 months,
whatever the OS data maturity, probably because these
patients receive many follow-up treatments.19 Therefore,
a meta-analysis of time-to-event outcomes, such as that pre-
sented herein, using hazard ratio as a measure to evaluate the
impact of a treatment, can be of value in aggregating available
evidence from different clinical trials.20
Figure 2. (continued).
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Concerning the combinations included in our analysis,
a hormonal agent combined with a targeted agent, and tar-
geted plus targeted agent combinations were the most com-
mon treatment arrangements. An important rationale of anti-
cancer drug combinations is avoidance of treatment
resistance.21,22 Indeed, it is well known that emerging resis-
tance mediated by activation of alternative pathways is com-
monly seen during treatment with hormonal and targeted
therapies.23,24 Also, the distinct mechanism of action of each
drug used in the combination could theoretically mitigate the
impact of tumor heterogeneity. These considerations may be
operative in the prolongation of PFS and OS seen with such
combinations.
The data presented here is relevant for tailoring drug combina-
tions.Although efficacy and safety endpoints are extremely impor-
tant, combinations should also be based on biological rationale.
Previous studies (mainly focused on monotherapies) demon-
strated that a biomarker-based rationale was associated with
increased efficacy of anticancer drugs.8,25 In our current data,
only 9% of randomized comparisons included a biomarker-
based rationale for the addition of the second agent. We adopted
the definition of a biomarker-based rationale as previously
reported in these studies. A differential benefit in efficacy was
not detected for this group, perhaps because of the paucity of
biomarker-based combination studies. Indeed, a previous report
including prospective clinical trials over a 5-year period, demon-
strated that there was a significant reduction in using biological or
molecular criteria for patient selection from phase I to phase III
studies (phase I: 41.1% vs. phase II: 29.3% vs. phase III: 3.1%).26
Hence, there is a need for future trials that explore the value of
biomarkers that select optimized combinations in individual
patients.
Our meta-analysis identified only a few immunotherapy
combinations, and the majority included two
immunotherapies. During immunotherapy drug development,
monotherapy was the initial approach. Pairing immunotherapy
with other immunotherapeutic or targeted agents, as well as
with radiation or cytotoxic chemotherapy, is a more recent
strategy, and many clinical trials exploring this dynamic field
are currently ongoing and/or are still in phase I or phase II
stages.27 The rationale for immunotherapy combinations
include bypassing immune evasion as well as targeting non-
redundant pathways, such as CTLA-4 and PD-L1.28,29 As far as
immunotherapy combinations, our meta-analysis demon-
strated that OS was significantly improved (HR 0.49 [0.33–-
0.74] p = .001), whereas PFS for combinations was not superior
compared to monotherapy (HR 0.64 [0.36–1.12] p = .11).
Recognition that unusually long duration of responses can
occur, responses after initial progression (pseudoprogression)
are possible, and also that responses may remain durable after
treatment withdrawal in patients receiving immunotherapy, are
important in understanding this discrepancy.30,31 More
recently, hyperprogression was also described as a pattern of
response to immune checkpoint inhibitors and might compro-
mise PFS as well.32,33 Further, traditional imaging response
criteria may not be suitable to detect PFS benefit of immu-
notherapeutic agents.34 A previous pooled meta-analysis eval-
uated correlation between PFS and OS outcomes for patients
who received PD-1 inhibitors and showed that, using
a random-effects meta-analysis, the protective effects of treat-
ment were greater for OS than for PFS, and there was no
significant correlation between OS and PFS in terms of med-
ians and gains in medians.35 Our meta-analysis supports this
observation, suggesting that OS should be included as
a primary endpoint in future phase 3 trials of immunotherapy
agents. It is important to recognize that inter- and intra-tumor
heterogeneity of the immune-microenvironment may affect the
results of immunotherapy combinations in each tumor type.
Table 3. Meta-analysis for the effects of combination therapies versus single agentsa upon high-grade toxicities
and treatment-related mortality (multivariateb).
High-grade toxicity Treatment-related mortality
N
OR (95% CI)
P value N
OR (95% CI)
P value
Overall
P-value
76 2.42 (1.98–2.97)
<0.001
87 1.33 (1.15–1.53)
<0.001
Class of experimental drug addedc
Targeted small molecule inhibitor
Targeted monoclonal antibody
Immunotherapy
Hormonal
Not classified
41
19
8
5
3
3.14 (2.49–3.97)
p < .001
1.81 (1.24–2.64)
p = .002
3.04 (1.76–5.28)
p < .001
1.62 (0.85–3.08)
p = .14
1.08 (0.43–2.72)
p = .86
47
18
10
6
6
1.49 (1.19–1.87)
p < .001
1.81 (1.33–2.46)
p < .001
1.67 (1.13–2.45)
p = .01
2.18 (1.43–3.32)
p < .001
0.53 (0.26–1.08)
p = .08
Phase of the Study
Phase II
Phase III
46
30
2.45 (1.82–3.31)
p < .0001
2.40 (1.80–3.19)
p < .0001
52
35
1.25 (0.93–1.67)
p = .13
1.72 (1.31–2.25)
p = .003
aSingle agents are the reference point for all statistics. The final model included the following variables: High-
Grade Toxicity (experimental drug class and linear toxicity rate in single arm); Treatment-related mortality
(experimental drug class and linear treatment mortality rate in single arm);
bEstimated ORs in each model are valid after accounting for a linear dependence on the appropriate rate in the
single arm. Model chosen using forward selection with entry p-value 0.10
cClass of experimental drug added to the backbone drug.
Abbreviations: N, number of randomized comparisons included; OR, odds ratio.
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Unfortunately, due to the low number of trials, specifically
addressing immunotherapy combinations, we could not pro-
ceed with sub-analysis by tumor type in this topicFor toxicity,
combination therapy clearly increased treatment-related side
effects and mortality, which was associated with the type of
drug added to the combination, and was most significant for
targeted small molecule inhibitors combined with immu-
notherapy drugs. Nevertheless, it is important to emphasize
that the incidence of deaths at least possibly related to single-
agent versus combination therapy was extremely low (0.95%
and 1.40%, respectively). Interestingly, in our analysis, drug
types that more intensively increased toxicity when added to
the single-agent backbone were targeted small molecules and
immunotherapies. Of relevance in this regard, phase I trials
with monoclonal antibodies frequently reveal an absence of
dose-limiting toxicities and dosing not limited by safety
parameters.36 On the other hand, targeted small molecules are
associated with more frequent dose-limiting toxicities,37 and
immunotherapies in combinations also amplify toxicities that
may limit dosing.38
The current study has several limitations. Amongst indivi-
dual trials, the totality of efficacy data, including RR, PFS, and
OS, were not uniformly reported, which may limit direct
comparisons of the effects on each efficacy endpoint. In
some trials, time-to-event endpoints were not the objective
of analysis, but it is unclear if possible omission of PFS or OS
(in part due to different follow-up times) would impact our
results. Additionally, we excluded randomized controlled stu-
dies that contained cytotoxic chemotherapy in any arm.
Therefore, studies with chemotherapy and immunotherapy
were excluded. A plethora of trials are currently being con-
ducted with these types of combinations, exploiting potential
immunomodulatory effects from chemotherapy.39 Such cyto-
toxic combination trials warrant further study in order to
assess overall impact on efficacy and safety endpoints. Our
analysis may also be affected by publication bias, which
usually favors positive trials. To minimize this bias we
searched a long period of time and included journals regard-
less of their impact, but further updates in this analysis may
be warranted. Finally, our study does not address the mechan-
isms of improved response and whether or not sequencing
strategies would be just as good as combinations. Of interest
in this regard, previous modeling has shown that, for many
combinations, the effects obtained could be explained by each
of the drugs working on an independent subset of patients,
rather than a synergistic mode of action.40 Very few trials
have been designed in oncology to test the hypotheses of
sequencing therapies,41 and this is a question that remains
open for future trials.
In conclusion, our findings provide the first evidence of the
overall impact of non-cytotoxic combinations on efficacy and
safety outcomes in solid tumors. Using data from 96 randomized
comparisons of single versus combination treatments focused on
immunotherapy, hormonal agents and gene-targeted agents
(29,175 patients), we demonstrated that adding another non-
cytotoxic drug considerably increased response rate, and pro-
longed progression-free and overall survival compared to
a single non-cytotoxic agent. Although non-cytotoxic agents in
combinations also increased toxicities, the weight of the evidence
points to the advantages of combinations based on an overall
survival gain. Our findings highlight the importance of non-
cytotoxic combinations in the treatment strategy of solid tumors.
A second implication of the results is that the effects of combina-
tions on efficacy and safety vary according to the class of drugs,
with this important finding demonstrated with immunothera-
pies. Future trial development should focus on improving the
effectiveness of cancer therapies exploring combinations of non-
cytotoxic agents, taking in account the different class effects
described herein.
Material and methods
Search strategy
We searched PubMed for published, randomized prospective
clinical trials that compared a single non-cytotoxic agent
(targeted therapy, hormonal agent or immunotherapy) with
the same agent combined with another non-cytotoxic agent.
We used the following terms: ((cancer OR neoplasm OR
carcinoma) AND (metastatic OR advanced)) and randomized
Clinical Trial, Phase III, Clinical Trial, Phase II. Our search
covered the period from 01/01/2001 to 03/06/2018. Trials
including a cytotoxic agent or radiotherapy in any arm were
excluded, as well as trials for a supportive or adjuvant setting,
or in pediatric population. Only advanced/metastatic solid
tumor trials were included. We categorized drug classes as
targeted small molecules, targeted monoclonal antibodies,
immunotherapy, hormonal therapy and as not classified
(defined in Table S1). We considered a “backbone drug” as
the agent that was present in both arms of the randomized
trial. The drug that was added to the backbone and present
only on one arm was considered as an “experimental drug.”
Whenever appropriate, we followed the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analysis)
statement.13,42
For immunotherapy combinations, randomized trials pre-
sented as abstracts were also searched through ASCO and ESMO
meetings between 2016 and March 2018.14,15,43,44 Only rando-
mized trials comparing combination vs. single-agent immu-
notherapies were selected for inclusion. The reason for this
expanded approach for immunotherapy is that results of numer-
ous of trials testing newer immunotherapies have just been
released and only few of them were published in manuscript
form. We included drug combinations regardless of their regula-
tory approval, to avoid a selection bias toward successful strategies
(Table S2).
Data extraction
Data extraction was conducted independently by two investiga-
tors (DLJ and DMG) and any discrepancies were resolved by
consensus in frequent meetings in the presence of the principal
investigator (RK). We considered response rate (RR), progres-
sion-free survival (PFS) or time to tumor progression (TTP)
when PFS was not available, and overall survival (OS) as accep-
table efficacy endpoints for analysis. For the analysis of time to
event endpoints (OS and PFS), only trials reporting hazard
rations were included. Responses were recorded according to
e1710052-10 D. L. JARDIM ET AL.
the response criteria adopted in the trial (Table S3). For the
safety analysis, we extracted the total percent of high-grade
treatment-related adverse events (AEs) described in each trial
and treatment-related mortality. Classification of the grade of
toxicity was per investigator's description. Alternatively, when
high-grade AEs were not described we extracted the percent of
treatment-related serious AEs, considering that the nomination
was used for both experimental and control arm. Trials that
only described the percent of high toxicity per type of toxicity
(and total incidence) were excluded. All deaths reported by
investigators as “possibly”, “probably”, or “definitely” related
to treatment were considered toxicity-related deaths.
Statistical analysis
Statistical analysis was performed by our biostatistician (DAB).
The statistical meta-analysis was done using a linear mixed-effects
model with potential fixed-effects of backbone drug class, experi-
mental drug class, diagnosis, whether there was a biomarker
rationale for the combination, and median prior regimens for
patients on the trial. In addition, for the odds ratio (OR) tests
(response rate, high-grade toxicity rate, and treatment-related
mortality rate), a polynomial dependence on the appropriate
rate in the backbone arm was considered as a possible covariate.
The models were fit using the metafor package (version 2.0–0) in
R (version 3.5.1), as described in Viechtbauer et al.16,45 The meta-
analysis models were fit using restricted maximum likelihood and
the Knapp and Hartung method.17,46 The final model was chosen
using forward selection with entry p-value 0.1. The risk of bias
was not applicable to this meta-analysis.
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